AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05132335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Biomarkers
Description: One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA(\[18F\]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water(\[15O\]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~\[18F\]-FTHA tracer injections \[15O\]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion
Study NCT05953584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.
Study NCT05953584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Participants will receive a stable dose of HU.
Study NCT06461104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Physical Activity Programme
Description: A somatic examination will also be conducted by a sports physician, which will include the assessment of muscle strength, cardiorespiratory fitness, walking gait, blood pressure, and body mass index (BMI). Based on this evaluation, the sports physician will design a personalised physical activity programme for the participants in the intervention group.
Study NCT06461104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Programme
Description: The control group undergoes a 12-week psychoeducational programme on nutrition and PA, consisting of 8 sessions. Led by a dietitian and psychologist, topics include PA benefits, healthy eating, and sedentary lifestyle risks. The experimental group receives 3 sessions on dietary habits before starting PA intervention, ensuring differentiation. It's expected the experimental group directly benefits from exercise, while the control group benefits from PA education. At the trial's end, control group members can join the PA programme for free.
Study NCT06461104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Programme
Description: The control group undergoes a 12-week psychoeducational programme on nutrition and PA, consisting of 8 sessions. Led by a dietitian and psychologist, topics include PA benefits, healthy eating, and sedentary lifestyle risks. The experimental group receives 3 sessions on dietary habits before starting PA intervention, ensuring differentiation. It's expected the experimental group directly benefits from exercise, while the control group benefits from PA education. At the trial's end, control group members can join the PA programme for free.
Study NCT04931654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: anti-PD-1 and anti-TIM-3 bispecific antibody
Study NCT06582888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate
Description: varenicline (target dose 1mg twice daily)
Study NCT06582888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study NCT06514586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin gel 600 IU . 1mg/g
Study NCT06514586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxypropyl methylcellulose
Description: Placebo
Study NCT05434897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280 Cream
Description: Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
Study NCT05434897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo cream
Description: Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
Study NCT03995004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.
Study NCT03995004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Sulphate 4mg/1mL
Description: Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
Study NCT03995004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Sulphate 4mg/1mL
Description: Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
Study NCT05895006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alpha-frequency tACS
Description: The investigators will apply a 2 mA sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup.
Study NCT05895006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alpha-frequency tACS
Description: The investigators will apply a 2 mA sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup.
Study NCT05895006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Random noise stimulation
Description: The investigators will apply a 2 mA sinusoid current oscillating at random frequency (1-200 Hz).
Study NCT05895006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Random noise stimulation
Description: The investigators will apply a 2 mA sinusoid current oscillating at random frequency (1-200 Hz).
Study NCT04575402 — intervention group
Intervention type: OTHER
Intervention: Wearable Activity Monitor
Description: Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
Study NCT06043557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drain Placement
Description: Surgical placement of drain based on subject randomization.
Study NCT06250725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: The intervention protocol will include CBTi principles like stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring. It will be done over 6 weeks with one session weekly via videoconference.
Study NCT05446311 — intervention group
Intervention type: DRUG
Intervention: Dinalbuphine sebacate
Description: After giving the birth, subjects are intramuscularly injected with a single dose of 150 mg of dinalbuphine sebacate (DS). DS is a prodrug of nalbuphine. After injeciton, DS are released to blood stream and hydrolyzed immediately. The onset of action is 12 to 24 hours and the analgesic effect can last about 5 to 7 days.
Study NCT06562036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Patients were given oral sildenafil as 2 mg per kg per day, 6-hourly with an increment of 0.5 mg per kg per dose and a target maintenance dose of 2 mg per kg per dose every 6 hour by nasogastric tube.
Study NCT06562036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: In this group, Milrinone was initiated at 0.5 ug per kg per minute using intravenous infusion through a syringe pump, and sildenafil was given in the same protocol mentioned for the Sildenafil Group.
Study NCT06129292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT group
Description: Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held.
Study NCT06023641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Low -risk Administer IV push over 1 minute (or infusion via minibag as per institutional standards) on Day 1 of Weeks 1,8, 15 (3) doses. The maximum dose is 2 mg for all participants.~Intermediate-risk Administer IV, over 1 minute, 3 doses, weekly on day1 High-risk Administer by IV infusion over 1 minute, 3 doses, weekly on day 1,8,15
Study NCT06023641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Low-risk Administer by slow IV push over 1-5 minutes on Day 1 of Weeks 1, (1) dose. The maximum dose is 2.5 mg for all participants.~Intermediate-risk Administer by slow IV over 1-5 minutes., 1 doses weekly on day 1 High-risk Administer by slow IV over 1-5 minutes, day1
Study NCT06023641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1
Study NCT06023641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Low, Intermediate and High-risk
Study NCT06023641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton beam radiation or external beam radiation or brachytherapy
Description: Low, Intermediate and High-risk
Study NCT06023641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan
Description: Intermediate and High-risk Administer by IV infusion over 90 minutes, 1 dose on day 1 Liposomal irinotecan should be premedicated with dexamethasone (or an equivalent corticosteroid) if not contraindicated. Premedication with diphenhydramine and an H2 receptor antagonist (i.e., famotidine) are also encouraged.
Study NCT06023641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Intermediate and High-risk Administer via slow IV push over 6-10 minutes (or infusion via minibag as per institutional standards) on Day 1 of Weeks 43-45, 47-49, 51-53, 55-57, 59-61, 63-65.
Study NCT06023641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: High-risk Administer PO (or by NG or G tube) 5 doses, on Days 1-5 When administering with liposomal irinotecan, administer temozolomide prior to liposomal irinotecan. Preferably, administer on an empty stomach (at least 1 hour before and 2 hours after food) to improve absorption. When using temozolomide capsules, round dose to the nearest 5 mg capsule. The capsule may be opened, and contents mixed with applesauce or apple juice. A compounded oral suspension is also available. If emesis occurs within 20 minutes of taking a dose of temozolomide, then the dose may be repeated once.
Study NCT06023641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, peg-filgrastim
Description: Low, Intermediate and High-risk:~Prophylactic myeloid growth factor support (Filgrastim or Pegfilgrastim) should be used after all VAC cycles for patients on the high-risk arm. Start myeloid growth factor support (for example, filgrastim 5 mcg/kg/dose SubQ daily until the ANC is ≥ 2000/μL after the expected nadir OR pegfilgrastim 0.1 mg/kg/dose \[for patients \< 45 kg\] or 6 mg/dose \[for patients ≥ 45 kg\] SubQ x 1 dose) 24-48 hours after VAC cycles. Filgrastim may be continued without regard to VCR. Discontinue filgrastim at least 24 hours before the start of the next cycle. Prophylactic myeloid growth factor support should NOT be used after VLIT cycles or during maintenance chemotherapy.
Study NCT06573918 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EMG-based assessment of paratonia
Description: EMG-assessed paratonia was analyzed and compared to assess motor response efficiency in three groups of healthy young adults with different levels of physical activity: professional athletes engaged in closed and open skills sports, amateurs, and sedentary individuals. To analyze EMG-assessed paratonia, two surface electrodes were attached to the biceps and triceps brachii muscles during passive flexion-extension movements of the elbow while the participant remained in a state of maximum relaxation. Any EMG activity detected during these movements was attributed to an inability to relax, thereby reflecting their degree of paratonia.
Study NCT06481150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Each tablet 30 mg
Study NCT06481150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05141045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 PUFA supplement
Description: participants were instructed to take 3.0 grams per day of omega-3 PUFA supplement
Study NCT05141045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT06215872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercises
Description: Participants who have inclusion criterias after DRF reconstrontion pos-op 4. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize or structered exercises pragram with telerehabilition during 4 weeks and 16 sessions. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
Study NCT06269328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total ıntravenous anesthesia with propofol and remifentanil for anesthetic maintenance
Description: For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia maintained with propofol iv 75-100 µg kg-1 min-1 and remifentanyl iv 0.05-0.2 µg kg-1 min-1 infusion.
Study NCT06269328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation anesthesia with sevoflurane for anesthetic maintenance
Description: For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia was maintained with inhalation anesthetic (50% O2/Air with Sevoflurane 2% )
Study NCT06215872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercises
Description: Participants who have inclusion criterias after DRF reconstrontion pos-op 4. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize or structered exercises pragram with telerehabilition during 4 weeks and 16 sessions. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
Study NCT06145828 — intervention group
Intervention type: DEVICE
Intervention: Cytokine Adsorption
Description: During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.
Study NCT05322603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)
Description: A decrease in the pain severity (VAS);opioid-sparing effect
Study NCT05322603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics
Description: A decrease in the pain severity (VAS)
Study NCT05949658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 5mg, 10mg, or 15mg once weekly sirolimus
Study NCT05245968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimitespib
Description: Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
Study NCT05245968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
Study NCT05949658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 5mg, 10mg, or 15mg once weekly everolimus
Study NCT05907044 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RQ3013
Description: 0.15mL/dose containing mRNA 30μg
Study NCT05907044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RQ3025
Description: 0.15mL/dose containing mRNA 30μg
Study NCT05907044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RQ3027
Description: 0.15mL/dose containing mRNA 30μg
Study NCT05245968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
Study NCT05268341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Sentence Builder
Description: computer-assisted treatment program for expressive grammar
Study NCT06385821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grippol Quadrivalent
Description: Solution for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
Study NCT06385821 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Grippol Plus
Description: Suspension for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly, 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
Study NCT06499935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Taping
Description: It is usually light brown or beige and is designed to hold firm, making it ideal for providing support or stability to a joint.
Study NCT06499935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio-Taping
Description: Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions.
Study NCT06499935 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Taping
Description: Sham taping is the use of any type of tape in a random and ineffective fashion for the purposes of comparison with other taping techniques and types.
Study NCT06471738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: BTK inhibitor
Study NCT06471738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal antibody to CD20
Study NCT06471738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: BCL-2 inhibitor
Study NCT06314698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlumosbart
Description: Administered by subcutaneous injection once every 4 weeks.
Study NCT06314698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 4 weeks.
Study NCT06571214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)
Description: As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.
Study NCT06571214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)
Description: This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.
Study NCT06571214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)
Description: This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.